Sue Friedman on Informed Decision-Making in Hereditary Cancers

Different subsets of patients with estrogen receptor-positive breast cancer achieved better pathologic complete response rates with neoadjuvant pembrolizumab/chemotherapy vs placebo/chemotherapy.

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

A consistent progression-free and overall survival benefit was reported among patients with hormone receptor-positive, HER2-negative advanced breast cancer, regardless of age.

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

Stephanie L. Graff, MD, FACP; Christine McGinn, MSN, APRN, ACNP-BC; and Jeanine Showalter, MSN, APRN, FNP-BC, AOCNP, share how they approach treatment decision-making following a brain metastasis.

Frontline cadonilimab (AK104) and platinum-based chemotherapy improved progression-free survival in patients with recurrent or metastatic cervical cancer.